9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex, Inc. Announces Third Quarter 2019 Financial Results

Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

Athenex Provides An Update to Shareholders

Athenex Provides An Update to Shareholders

Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

Athenex Completes Construction of New API Facility in Chongqing

Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.